Rigel Pharmaceuticals (RIGL) Accumulated Expenses (2010 - 2026)

Rigel Pharmaceuticals has reported Accumulated Expenses for 17 years, with the latest figure at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses changed 0.25% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (changed 0.25% YoY), and the FY2025 full-year result was $11.9 million, up 17.51% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.0 million, down from $11.9 million in the prior quarter.
• The five-year high for Accumulated Expenses was $11.9 million in Q4 2025, with the low at $5.2 million in Q1 2024.
• Average Accumulated Expenses over 5 years is $7.8 million, with a median of $7.9 million recorded in 2025.
• Year-over-year, Accumulated Expenses fell 17.06% in 2022 and climbed 27.02% in 2025.
• Tracing RIGL's Accumulated Expenses over 5 years: stood at $8.9 million in 2022, then slipped by 2.14% to $8.7 million in 2023, then rose by 16.86% to $10.1 million in 2024, then increased by 17.51% to $11.9 million in 2025, then sank by 49.56% to $6.0 million in 2026.
• The last three Accumulated Expenses figures came in at $6.0 million (Q1 2026), $11.9 million (Q4 2025), and $10.1 million (Q3 2025), per Business Quant data.

Peer Comparison